Very recently, a few studies have explored other tumor-promoting changes that occur in cancers with ATRX deficiency, including increased cellular motility in glioma cells and TGF-β activation with CDH1 (E-cadherin) downregulation in liver cancer cells (16, 32, 33). The gene discussed is ATRX; the disease is central nervous system cancer.